Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Roche implements risk mitigation plan in taspoglutide Phase III programme

Ipsen, a global biopharmaceutical group, today announced that its partner Roche today announced the implementation of a risk mitigation plan in the taspoglutide Phase III programme. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.

18 Jun 2010

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

Metabolon, Inc., the leader in metabolomics-based biomarker discovery and analysis, today announced the publication of research that identified a novel, early biomarker for insulin resistance and glucose intolerance in a nondiabetic population.

17 Jun 2010

St. Jude Medical commences enrollment in LAPTOP-HF study

St. Jude Medical, Inc., a global medical device company, today announced the first enrollment in its LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy) study. The goal of the LAPTOP-HF study is to demonstrate that the new investigational left atrial pressure (LAP) management system safely and effectively improves outcomes in patients with heart failure (HF).

17 Jun 2010

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. at a company per-money valuation of 170 million US dollars.

17 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

Researchers identify peptide that triggers diabetes

Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.

17 Jun 2010

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

Adi Mehta, MD stresses the growing severity of the metabolic syndrome in the May 2010 edition of Postgraduate Medicine. Metabolic syndrome often leads to cardiovascular disease (CVD) because of its key components: diabetes, dyslipidemia, and hypertension. With obesity maintaining its status as a huge problem worldwide, physicians must act as soon as possible when they recognize metabolic syndrome or any of its components.

16 Jun 2010

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

An article published in the May 2010 issue of Postgraduate Medicine highlights the seriousness of cardiovascular disease (CVD) in patients with type 2 diabetes. Cardiovascular disease is the cause of death in > 65% of patients with diabetes, and when complicated by the presence of obesity, the lifetime risk of developing CVD increases to 90%. The inherent problem is that many of the antihyperglycemic medications used to combat high glycated hemoglobin are associated with weight gain and/or hypoglycemia, which negatively affect CVD.

16 Jun 2010

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

Type 2 diabetes is characterized by unsatisfactory levels of glycated hemoglobin (HbA1c) for extended periods. An article published in the May 2010 edition of Postgraduate Medicine reports a proposal to shorten the total time spent with uncontrolled hyperglycemia by minimizing the number of steps along the treatment-intensification ladder. In doing so, patients would decrease their exposure to hyperglycemia and potentially improve long-term outcomes.

16 Jun 2010

European market for continuous glucose monitoring to reach $52M in 2016

The continuous glucose monitoring (CGM) market is in its development stage. The primary factor leading to the growth of the (CGM) market in Europe is the need for an easy-to-use and patient-friendly glucose-monitoring device. The traditional method of monitoring glucose was difficult and inconvenient for patients. The CGM method is not only hassle-free, but also gives a better diagnosis of diabetes.

16 Jun 2010

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

A hormone that helps to regulate blood sugar levels may also influence a person's sensitivity to sweet-tasting foods, according to a new study from researchers at the University of Maryland School of Medicine. They found that blocking the tongue's ability to respond to the hormone known as glucagon decreases the taste system's sensitivity to sweetness.

16 Jun 2010

Diabetes associated with increased risk of cancer

A new consensus statement of experts assembled by the American Diabetes Association and the American Cancer Society reviews emerging evidence that suggests cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. The new report reviews the state of science concerning the association between diabetes and cancer incidence/prognosis; risk factors common to both diseases; possible biologic links between diabetes and cancer risk; and whether diabetes treatments influence the risk of cancer or cancer prognosis.

16 Jun 2010

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

BIOCIUS Life Sciences Inc., developers of the RapidFire® high-throughput mass spectrometry system, and BlueSky Biotech, service provider of discovery biologicals, today announced their collaboration to offer the industry's only Sirtuin (SIRT, silent mating type information regulation homolog) enzyme preparations fully-validated in a label-free functional assay.

16 Jun 2010

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

Researchers from the Peninsula Medical School, working in collaboration with colleagues from Glasgow Royal Infirmary and the University of Brighton, have used a unique collection of pancreas specimens taken from patients who died soon after diagnosis of type 1 diabetes to show that they respond to the ongoing process of destruction by inducing their islet cells to proliferate.

15 Jun 2010

ConjuChem second-quarter net loss decreases to $3.6 million

ConjuChem Biotechnologies today announced financial results for the second quarter of fiscal 2010, ended April 30, 2010.

15 Jun 2010

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Biodel Inc. announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 70th Scientific Sessions of the American Diabetes Association this month in Orlando, Florida:

14 Jun 2010

Chiasma successfully completes Phase I clinical study of Octreolin

Chiasma, Inc., a privately held biopharma company, announced that it has successfully completed a Phase I clinical study evaluating the safety and pharmacokinetics (PK) of its proprietary product Octreolin, which contains the active ingredient octreotide actetate and is administered orally

14 Jun 2010

Insulin News and Research

Further Reading

Roche implements risk mitigation plan in taspoglutide Phase III programme

Research identifies early biomarker for insulin resistance, glucose intolerance in nondiabetic population

St. Jude Medical commences enrollment in LAPTOP-HF study

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Researchers identify peptide that triggers diabetes

Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome

New perspectives in type 2 diabetes, cardiovascular risk, and treatment goals

How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation

European market for continuous glucose monitoring to reach $52M in 2016

Hormone that helps regulate blood sugar levels may influence sensitivity to sweet-tasting foods: Study

Diabetes associated with increased risk of cancer

BIOCIUS Life Sciences, BlueSky Biotech collaborate to offer Sirtuin pre-validated assay solution

Insulin-producing beta cells can proliferate in patients recently diagnosed with type 1 diabetes: Researchers

ConjuChem second-quarter net loss decreases to $3.6 million

Biodel announces schedule for presentations at 70th Scientific Sessions of American Diabetes Association

Chiasma successfully completes Phase I clinical study of Octreolin

In vivo structure of senile plaques in brains of people with Alzheimer's disease

CinGx safe and effective for treating diabetes, Alzheimer’s and dementia

sanofi pasteur congratulates Canadian Public Health Association for 100 years of leadership and service

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News